JPS62249927A - 蛋白物質および抗腫瘍剤 - Google Patents
蛋白物質および抗腫瘍剤Info
- Publication number
- JPS62249927A JPS62249927A JP61092354A JP9235486A JPS62249927A JP S62249927 A JPS62249927 A JP S62249927A JP 61092354 A JP61092354 A JP 61092354A JP 9235486 A JP9235486 A JP 9235486A JP S62249927 A JPS62249927 A JP S62249927A
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- substance
- water
- toxoplasma
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 title claims abstract description 38
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 9
- 241000223997 Toxoplasma gondii Species 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 239000004480 active ingredient Substances 0.000 claims description 3
- 108010029907 obioactin Proteins 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 7
- 230000000259 anti-tumor effect Effects 0.000 abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 6
- 239000007788 liquid Substances 0.000 abstract description 5
- 239000000047 product Substances 0.000 abstract description 5
- 241000223996 Toxoplasma Species 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 239000012153 distilled water Substances 0.000 abstract description 3
- 238000000703 high-speed centrifugation Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 239000011780 sodium chloride Substances 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 239000000644 isotonic solution Substances 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract 2
- 239000006228 supernatant Substances 0.000 abstract 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 238000009210 therapy by ultrasound Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000411 inducer Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- -1 light mineral oil Substances 0.000 description 2
- 229940059904 light mineral oil Drugs 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150084935 PTER gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61092354A JPS62249927A (ja) | 1986-04-23 | 1986-04-23 | 蛋白物質および抗腫瘍剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61092354A JPS62249927A (ja) | 1986-04-23 | 1986-04-23 | 蛋白物質および抗腫瘍剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62249927A true JPS62249927A (ja) | 1987-10-30 |
| JPH0567159B2 JPH0567159B2 (fr) | 1993-09-24 |
Family
ID=14052065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61092354A Granted JPS62249927A (ja) | 1986-04-23 | 1986-04-23 | 蛋白物質および抗腫瘍剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62249927A (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013543493A (ja) * | 2010-10-01 | 2013-12-05 | アムリタ セラピューティクス リミテッド | 抗がん剤 |
-
1986
- 1986-04-23 JP JP61092354A patent/JPS62249927A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013543493A (ja) * | 2010-10-01 | 2013-12-05 | アムリタ セラピューティクス リミテッド | 抗がん剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0567159B2 (fr) | 1993-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6391325A (ja) | 顆粒球コロニ−刺激因子を含有する徐放性製剤 | |
| IL129211A (en) | Use of colostrinin in the manufacture of a medicament for the treatment of central nervous system disorders | |
| JPS58889A (ja) | 改良されたキモパパイン及びその製法ならびに用途 | |
| US4250084A (en) | Purified thymic hormone (THF), its preparation and pharmaceutical compositions containing it | |
| JPH0427964B2 (fr) | ||
| JPH07101875A (ja) | 膀胱ガンに対して高い抗腫瘍活性を有するカサガイヘモシアニン | |
| ES2915380T3 (es) | Procedimiento de producción de una sustancia con actividad antimicrobiana, antiviral e inmunoestimuladora, una sustancia y una composición | |
| JPS58141785A (ja) | 抗腫瘍物質の製法 | |
| JPS62249927A (ja) | 蛋白物質および抗腫瘍剤 | |
| ES2263859T3 (es) | Composiciones qu4e comprenden hemoglobina fetal y endotoxina bacteriana y opcionalmente componentes de higado fetal adicionales. | |
| RU2041717C1 (ru) | Биологически активное средство, способ его получения и препарат, содержащий указанное средство, и способ использования препарата | |
| US4056614A (en) | Immunity depressant medicine | |
| JP3172599B2 (ja) | 細胞賦活剤 | |
| US20190234933A1 (en) | Compositions and assays | |
| JPH09227392A (ja) | 抗腫瘍剤及びその製造法 | |
| RU2221591C1 (ru) | Способ получения препарата для активной иммунизации против туляремии | |
| RU2203070C2 (ru) | Способ получения иммунотропных веществ из кожи свиньи | |
| JPH07504202A (ja) | ロイキンフェロン製剤 | |
| US4877616A (en) | Process for preparing xerosin II and xerosin III, improved biological response modifiers | |
| JPH03505200A (ja) | 治療活性のある、特に傷治療または老人医学に用いる作用物質およびかかる作用物質を含む製剤の製造方法 | |
| RU2128513C1 (ru) | Способ получения лечебного средства, регулирующего дифференциацию клетки | |
| RU2134581C1 (ru) | Средство для лечения облученных млекопитающих | |
| JP2000290194A (ja) | 病原性細菌およびウイルス感染防御剤 | |
| EP0673653B1 (fr) | Agent biologiquement actif ayant des proprietes d'immunomodulation, procede pour sa production et preparation pharmaceutique a base de cet agent | |
| AU783851B2 (en) | Method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent |